Premium
Does tocilizumab have a role in dermatology? A review of clinical applications, its adverse side effects and practical considerations
Author(s) -
Choong Dean Jeremy,
Tan Ernest
Publication year - 2021
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14990
Subject(s) - tocilizumab , medicine , pyoderma gangrenosum , dermatology , etanercept , adverse effect , psoriasis , rheumatoid arthritis , atopic dermatitis , adalimumab , cutaneous sarcoidosis , infliximab , tofacitinib , disease , immunology , sarcoidosis
Tocilizumab is a humanized monoclonal antibody to the interleukin‐6 (IL‐6) receptor which was first approved for use in refractory rheumatoid arthritis almost a decade ago. Since then, its use has expanded to a number of rheumatological and inflammatory conditions. In dermatology, off‐label use of tocilizumab has been reported to be efficacious in morphoea, systemic sclerosis, psoriasis, atopic dermatitis, vitiligo, graft‐versus‐host disease, pyoderma gangrenosum, Behcet's disease, Schnitzler's syndrome, sarcoidosis, and cutaneous adverse reactions. That being said, the evidence demonstrating tocilizumab's efficacy in dermatology is predominantly low‐level case‐based evidence, and one must consider the potential for publication bias. In this review we will discuss the reported clinical applications of tocilizumab in dermatology, mechanisms of action, and the range of associated adverse effects (both cutaneous and non‐cutaneous) that can occur. Additionally, we will discuss the role of tocilizumab in the management of COVID‐19.